1 month StockNews.com Upgrades Esperion Therapeutics (NASDAQ:ESPR) to BuyMarketBeat
StockNews.com upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday.
XStockNews.com upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday.
X